Related Experiment Videos
Perils with Pirfenidone and "the tuberculosis link"
Madhav H Hande1, K Vishak Acharya2, A Shreenivasa2
1Department of Medicine, Kasturba Medical College, MAHE, Mangalore, Karnataka, India.
International Journal of Mycobacteriology
|September 13, 2019
Summary
Patients with idiopathic pulmonary fibrosis (IPF) on pirfenidone may face an increased risk of developing tuberculosis (TB). A rare skin reaction, exfoliative dermatitis, occurred due to pirfenidone and rifampicin interaction.
Area of Science:
- Pulmonology
- Infectious Diseases
- Dermatology
Background:
- Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease.
- Pirfenidone is an antifibrotic medication used to treat IPF.
- Tuberculosis (TB) is an infectious disease primarily affecting the lungs.
Observation:
- A patient diagnosed with IPF and treated with pirfenidone developed TB.
- The patient later experienced exfoliative dermatitis, a severe skin reaction.
- This dermatitis was attributed to an interaction between pirfenidone and rifampicin, an anti-TB drug.
Findings:
- This case suggests a potential increased risk of TB in IPF patients receiving antifibrotic therapy.
- A previously undocumented adverse drug reaction involving pirfenidone and rifampicin was observed.
- The interaction led to severe exfoliative dermatitis.
Implications:
- Clinicians should consider the risk of TB in IPF patients on pirfenidone.
- Awareness of this potential drug interaction is crucial for managing co-existing TB and IPF.
- Further investigation into pirfenidone-rifampicin interactions and associated dermatological reactions is warranted.